Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Conditions:   Oncology;   Infusion Reaction Interventions:   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Ipilimumab;   Drug: Durvalumab;   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Trastuzumab Sponsor:   Isala Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials